Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vectura Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vectura Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Vectura Group Plc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
SkyePharma Acquires Novel Inhaled Therapy Platform from Pulmagen Therapeutics 13
Partnerships 14
Ablynx Exercises Option for Licensing Agreement with Vectura 14
Vectura Enters into Agreement with Dynavax Technologies 15
Vectura Enters into Development and License Agreement with Janssen Biotech 16
Activaero Enters Into Research Agreement With Stanford University 17
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 18
Activaero Enters Into Research Agreement With Chiesi Farmaceutici 19
Vectura, Tianjin KingYork Group And Zendex Bio Strategy Form Respiratory Joint Venture In China 20
Activaero Enters Into Co-Development Agreement With TransMIT 21
Tianjin KingYork Forms Joint Venture With Innovata For Asthma And COPD Drugs 22
Merger 23
SkyePharma Merges with Vectura 23
Licensing Agreements 25
Vectura Group Enters into Licensing Agreement with Pulmatrix 25
Sandoz Enters into Licensing Agreement with Vectura 26
Mundipharma Enters into Licensing Agreement with Vectura for VR2076 27
Skyepharma Enters into Licensing Agreement with Lucideon 28
Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 29
SkyePharma Enters into Option Agreement with Mundipharma 30
Vectura Enters into Licensing Agreement with US-Based Pharma Company for VR506 31
Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 32
Equity Offering 33
SkyePharma Completes Private Placement Of Shares For US$187 Million 33
SkyePharma Completes Rights Offering Of Shares 34
Vectura Group Completes Private Placement Of Shares For US$46 Million 35
Ventaleon Spin Out from Activaero 36
Acquisition 37
GlaxoSmithKline May Acquire Vectura for USD1.62 Billion 37
Vectura Acquires Activaero, Medical Device Company, For US$181 Million 38
Vectura Group Plc – Key Competitors 40
Vectura Group Plc – Key Employees 41
Vectura Group Plc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Sep 11, 2018: Vectura Group: Interim Results 43
Mar 21, 2018: Vectura Group: 2017 Preliminary Results 52
Mar 21, 2018: Vectura Group: 2017 Preliminary Results – Performance in-line with expectations, with strong in-market growth from key inhaled products 53
Sep 06, 2017: Vectura Group: 2017 Interim Results 55
Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016 57
Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016 59
Corporate Communications 60
Oct 22, 2018: Vectura group has announced the board change 60
Jul 16, 2018: Vectura Appoints Paul Fry as Chief Financial Officer and Executive Director 61
Jun 01, 2018: Vectura Group Appoints Anne Whitaker As Non-Executive Director 62
Apr 20, 2018: Vectura Announces Senior Management Change 63
Apr 20, 2018: Vectura Group: Directorate Change – Chief Financial Officer 64
Mar 06, 2017: Vectura Group: Board Change 65
Clinical Trials 66
May 22, 2017: Positive outcomes of the Phase I clinical study on VR942 presented at the American Thoracic Society 113th annual conference 66
Jan 24, 2017: FDA approves IND to support Vectura’s wholly-owned programme VR647 in paediatric asthma 67
Other Significant Developments 68
Oct 24, 2017: Vectura Group: Ultibro Breezhaler continues to deliver strong underlying growth in Q3 68
Feb 16, 2017: Vectura achieves £9 million royalty cap from GSK Ellipta® products 69
Jan 11, 2017: Vectura Group: Pre-close update 70
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71
Vectura Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vectura Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vectura Group Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Vectura Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
SkyePharma Acquires Novel Inhaled Therapy Platform from Pulmagen Therapeutics 13
Ablynx Exercises Option for Licensing Agreement with Vectura 14
Vectura Enters into Agreement with Dynavax Technologies 15
Vectura Enters into Development and License Agreement with Janssen Biotech 16
Activaero Enters Into Research Agreement With Stanford University 17
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 18
Activaero Enters Into Research Agreement With Chiesi Farmaceutici 19
Vectura, Tianjin KingYork Group And Zendex Bio Strategy Form Respiratory Joint Venture In China 20
Activaero Enters Into Co-Development Agreement With TransMIT 21
Tianjin KingYork Forms Joint Venture With Innovata For Asthma And COPD Drugs 22
SkyePharma Merges with Vectura 23
Vectura Group Enters into Licensing Agreement with Pulmatrix 25
Sandoz Enters into Licensing Agreement with Vectura 26
Mundipharma Enters into Licensing Agreement with Vectura for VR2076 27
Skyepharma Enters into Licensing Agreement with Lucideon 28
Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 29
SkyePharma Enters into Option Agreement with Mundipharma 30
Vectura Enters into Licensing Agreement with US-Based Pharma Company for VR506 31
Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 32
SkyePharma Completes Private Placement Of Shares For US$187 Million 33
SkyePharma Completes Rights Offering Of Shares 34
Vectura Group Completes Private Placement Of Shares For US$46 Million 35
Ventaleon Spin Out from Activaero 36
GlaxoSmithKline May Acquire Vectura for USD1.62 Billion 37
Vectura Acquires Activaero, Medical Device Company, For US$181 Million 38
Vectura Group Plc, Key Competitors 40
Vectura Group Plc, Key Employees 41
Vectura Group Plc, Subsidiaries 42
List of Figures
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vectura Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
【免責事項】
http://www.globalresearch.jp/disclaimer